The acquisition is subject to shareholder approval. The investment will enhance Australia’s position as a provider of outstanding oncology care by delivering capital and expertise to help grow Icon’s services locally and internationally.
Headquartered in Brisbane and operating throughout Australia, Icon is Australia’s largest private day oncology provider. Icon has expanded to Singapore, China and New Zealand, and is poised for further regional expansion. The Group’s comprehensive state-of-the-art cancer care includes radiation oncology, day oncology hospitals, pharmacy and chemotherapy compounding. Icon is highly successful at bringing these services to previously under-served locations.